Clinical trial · no report yet · Phase 1
DeLLphi-300
Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
- NCT03319940 ↗
- Active, not recruiting
- Amgen
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 17 | |
| YouTube | 8 | |
| Podcasts | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- Tarlatamab; Pembrolizumab; CRS Mitigation Strategies
- Arms
- Part A · Experimental
- Part C · Experimental
- Part D · Experimental
- Part E · Experimental
- Part F · Experimental
- Part G · Experimental
- Enrollment
- 269
- Primary outcomes
- Number of participants with dose limiting toxicities (DLT) for all indications
- Number of participants with treatment-emergent adverse events (AEs) for all indications
- Number of participants with treatment-related AEs for all indications
- Number of participants with clinically significant changes in vital signs for all indications
- Number of participants with significant changes in electrocardiogram (ECG) for all indications
- Number of participants with significant changes in physical examinations for all indications
- Number of participants with significant changes in clinical laboratory tests for all indications
- Sponsor
- Amgen
- Start
- Dec 26, 2017
- Primary completion
- Dec 31, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT03319940 · updated Nov 19, 2025
Publications
linked from the registry- Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K. DLL3: an emerging target in small cell lung cancer. J Hematol Oncol. 2019 Jun 18;12(1):61. doi: 10.1186/s13045-019-0745-2. PubMed 31215500
- Dowlati A, Hummel HD, Champiat S, Olmedo ME, Boyer M, He K, Steeghs N, Izumi H, Johnson ML, Yoshida T, Bouchaab H, Borghaei H, Felip E, Jost PJ, Gadgeel S, Chen X, Yu Y, Martinez P, Parkes A, Paz-Ares L. Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update. J Clin Oncol. 2024 Oct 10;42(29):3392-3399. doi: 10.1200/JCO.24.00553. Epub 2024 Aug 29. PubMed 39208379
- Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, Hummel HD, Borghaei H, Johnson ML, Steeghs N, Blackhall F, Dowlati A, Reguart N, Yoshida T, He K, Gadgeel SM, Felip E, Zhang Y, Pati A, Minocha M, Mukherjee S, Goldrick A, Nagorsen D, Hashemi Sadraei N, Owonikoko TK. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903. doi: 10.1200/JCO.22.02823. Epub 2023 Jan 23. PubMed 36689692
- Chiang AC, Olmedo Garcia ME, Carlisle JW, Dowlati A, Reguart N, Felip E, Jost PJ, Steeghs N, Stec R, Gadgeel SM, Loong HH, Jiang W, Hamidi A, Parkes A, Paz-Ares L. Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy. ESMO Open. 2025 Apr;10(4):104538. doi: 10.1016/j.esmoop.2025.104538. Epub 2025 Apr 4. PubMed 40187110